{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T22:24:47Z","timestamp":1792448687359,"version":"4.5.0"},"reference-count":29,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T00:00:00Z","timestamp":1724284800000},"content-version":"vor","delay-in-days":21,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Immunity Inflam &amp;amp; Disease"],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Study Design<\/jats:title><jats:p>Lupus nephritis (LN) is an autoimmune disease as a complication of systemic lupus erythematosus (SLE). LN is typically diagnosed through a combination of clinical evaluation as index scoring, and kidney biopsy as a more accurate but invasive examination. In the current study, we assessed serological markers including IFN\u2010\u03b3\u2010inducible chemokines C\u2010X\u2010C motif chemokine ligand (CXCL)9, CXCL10, and CXCL11 in diagnosing LN.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A retrospective analysis was conducted on 160 SLE patients with and without LN. Fasting venous blood was collected from the study subjects for measuring serum levels of CXCL9, CXCL10, and CXCL11. The assessment of clinical disease activity in SLE was conducted using the\u00a0SLE Disease Activity Index\u00a0(SLEDAI)\u20102000 scoring system. LN disease activity was conducted using the Austin scoring system. LN was further confirmed following kidney biopsy, and data were compared by receiver operating characteristic\u00a0(ROC) analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>SLE patients with LN showed longer SLE duration, enhanced SLEDAI scores, lower serum anti\u2010ds\u2010DNA antibody levels when compared to SLE patients without LN. Specifically, these patients had significantly higher serum levels of CXCL9, CXCL10 and CXCL11. CXCL9, CXCL10, and CXCL11 showed positive correlation with SLE disease activity in SLE patients with LN. ROC\u00a0analysis of CXCL9, CXCL10, and CXCL11 showed substantial enhancement of sensitivity and specificity for the diagnosis of LN in the patients with SLE.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Serum CXCL9, CXCL10, and CXCL11 levels may improve the sensitivity and specificity for the diagnosis of LN in SLE patients.<\/jats:p><\/jats:sec>","DOI":"10.1002\/iid3.1368","type":"journal-article","created":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T21:23:16Z","timestamp":1724361796000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Clinical significance of serum CXCL9, CXCL10, and CXCL11 in patients with lupus nephritis"],"prefix":"10.1002","volume":"12","author":[{"given":"Shuo","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Nephrology Zibo Central Hospital Zibo China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-7540-6689","authenticated-orcid":false,"given":"Yanhui","family":"Cui","sequence":"additional","affiliation":[{"name":"Department of Rheumatism Immunity Zibo Central Hospital Zibo China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,8,22]]},"reference":[{"key":"e_1_2_10_2_1","first-page":"221","article-title":"Predicting patients who are likely to develop lupus nephritis of those newly diagnosed with systemic lupus erythematosus","volume":"2022","author":"Bechler KK","year":"2022","journal-title":"AMIA. Annual Symposium proceedings. AMIA Symposium"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-023-05469-1"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2023.2264172"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224197"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.3390\/genes14030537"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/7176515"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.954706"},{"key":"e_1_2_10_9_1","first-page":"4067","article-title":"Increased expression of hub gene CXCL10 in peripheral blood mononuclear cells of patients with systemic lupus erythematosus","volume":"18","author":"Zhang R","year":"2019","journal-title":"Exp Ther Med"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar4451"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-024-01401-4"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2990.2010.01089.x"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2017.11.007"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.12.029"},{"key":"e_1_2_10_15_1","first-page":"288","article-title":"Systemic lupus erythematosus disease activity index 2000","volume":"29","author":"Gladman DD","year":"2002","journal-title":"J Rheumatol"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-023-05426-y"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1177\/0961203310364400"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.3389\/fneph.2022.984613"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.reuma.2023.03.002"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1177\/09612033231201619"},{"key":"e_1_2_10_21_1","article-title":"Unmasking renal disease in systemic lupus erythematosus: beyond lupus nephritis","volume":"15","author":"Nunez Cuello L","year":"2023","journal-title":"Cureus"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2021-000631"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.4049\/immunohorizons.2000005"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/6660164"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1177\/0961203313484977"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0241719"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2010-2905"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.3109\/s10165-011-0565-x"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2009.04813.x"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/6012715"}],"container-title":["Immunity, Inflammation and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/iid3.1368","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T10:53:20Z","timestamp":1726138400000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/iid3.1368"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":29,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["10.1002\/iid3.1368"],"URL":"https:\/\/doi.org\/10.1002\/iid3.1368","archive":["Portico"],"relation":{},"ISSN":["2050-4527","2050-4527"],"issn-type":[{"value":"2050-4527","type":"print"},{"value":"2050-4527","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"2023-12-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e1368"}}